NKGN (NKGen Biotech) EBITDA Margin %: 0.00% (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is NKGen Biotech EBITDA Margin %?

NKGen Biotech NKGN EBITDA Margin % is 0.00% as of Mar. 2025.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. NKGen Biotech's EBITDA for the three months ended in Mar. 2025 was $16.24 Mil. NKGen Biotech's Revenue for the three months ended in Mar. 2025 was $0.00 Mil. Therefore, NKGen Biotech's EBITDA margin for the quarter that ended in Mar. 2025 was 0.00%.

NKGen Biotech  (OTCPK:NKGN) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

NKGen Biotech EBITDA Margin % Related Terms

NKGen Biotech EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for NKGen Biotech's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NKGen Biotech EBITDA Margin % Chart

NKGen Biotech Annual Data
Trend Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
-4,859.39 -30,170.13 0.00 0.00

NKGen Biotech Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NKGN vs CALC, CLGN, MBRX: EBITDA Margin % Comparison

For the Biotechnology subindustry, NKGen Biotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NKGen Biotech EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NKGen Biotech's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where NKGen Biotech's EBITDA Margin % falls into.


NKGen Biotech EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

NKGen Biotech's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-40.194/0
= %

NKGen Biotech's EBITDA Margin % for the quarter that ended in Mar. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2025 )/Revenue (Q: Mar. 2025 )
=16.238/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
NKGen Biotech (NKGN) has a EBITDA Margin % of 0.00% as of Mar. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on NKGen Biotech and its competitors.
Is NKGen Biotech's EBITDA Margin % too high?
NKGen Biotech's current EBITDA Margin % is 0.00%.
How does NKGen Biotech's EBITDA Margin % compare to CALC and CLGN?
NKGen Biotech's EBITDA Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on NKGen Biotech and its competitors. NKGen Biotech's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NKGen Biotech stock overvalued right now?
NKGen Biotech (NKGN) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For NKGen Biotech (NKGN), the current EBITDA Margin % is 0.00% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NKGen Biotech Business Description

Address 3001 Daimler Street, Santa Ana, CA, USA, 92705
NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.